GIV-IN PV TRIAL

Trial overview

Disease

Blood cancer

Sponsor

Italfarmaco

Enquire

Description

Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL

Study details

For detailed information on this trial, please click here

Trial status

Opening August 2025

Location

Oxford

Principal Investigator

Dr Adam Mead

MBBS, MD, FRCP, FRCPath

Consultant Haematologist